Literatur
- 1
Abrahamsen B, Hangaard J, Horn H C, Hansen T B, Gregersen G, Hansen-Nord M. et al
.
Evaluation of the optimum dose of growth hormone (GH) for restoring bone mass
in adult-onset GH deficiency: results from two 12-month randomized studies.
Clin Endocrinol.
2002;
57
273-281
- 2
Ahmad A M, Thomas J, Clewes A, Hopkins M T, Guzder R, Ibrahim H. et al .
Effects of growth hormone replacement on parathyroid hormone sensitivity and
bone mineral metabolism.
J Clin Endocrinol Metab.
2003;
88
2860-2868
- 3
Aloia J F, Zanzi I, Ellis K, Jowsey J, Roginsky M, Wallach S, Cohn S H.
Effects of growth hormone in osteoporosis.
J Clin Endocrinol Metab.
1976;
43
992-999
- 4
Aloia J F, Vaswani A, Kapoor A, Yeh J K, Cohn S H.
Treatment of osteoporosis with calcitonin, with and without growth hormone.
Metabolism.
1985;
34
124-129
- 5
Aloia J F, Vaswani A, Meunier P J, Edouard C M, Arlot M E, Yeh J K, Cohn S H.
Coherence treatment of postmenopausal osteoporosis with growth hormone and calcitonin.
Calcif Tissue Int.
1987;
40
253-259
- 6
Amato G, Carella C, Fazio S, LaMontagna G, Cittadini A, Sabatini D. et al .
A Body composition, body metabolism and heart structure and function in growth
hormone (GH)-deficient adults before and after GH replacement therapy at low
doses.
J Clin Endocrinol Metab.
1993;
77
1671-1676
- 7
Amato G, Izzo G, La Montagna G, Bellastella A.
Low dose recombinant human growth hormone normalizes bone metabolism and cortical
bone density and improves trabecular bone density in growth hormone deficient
adults without causing adverse effects.
Clin Endocrinol.
1996;
45
27-32
- 8
Balducci R, Toscano V, Pasquino A M, Mangiantini A, Municchi G, Armenise P. et al
.
Bone turnover and bone mineral density in young adult patients with panhypopituitarism
before and after long-term growth hormone therapy.
Eur J Endocrinol.
1995;
132
42-46
- 9
Baroncelli G I, Bertelloni S, Sodini F, Saggese G.
Longitudinal changes of lumbar bone mineral density (BMD) in patients with GH
deficiency after discontinuation of treatment at final height: timing and peak
values for lumbar BMD.
Clin Endocrinol.
2004;
60
175-184
- 10
Baum H B, Biller B M, Finkelstein J S, Cannistraro K B, Oppenhein D S, Schoenfeld D A.
et al .
Effects of physiologic growth hormone therapy on bone density and body composition
in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled
trial.
Ann Intern Med.
1996;
125
883-890
- 11
Beshyah S A, Kyd P, Thomas E, Fairney A, Johnston D G.
The effects of prolonged growth hormone replacement on bone metabolism and bone
mineral density in hypopituitary adults.
Clin Endocrinol.
1995;
42
249-254
- 12
Bex M, Abs R, Maiter D, Beckers A, Lamberigts G, Bouillon R.
The effects of growth hormone replacement therapy on bone metabolism in adult-onset
growth hormone deficiency: a 2-year open randomized controlled multicenter trial.
J Bone Miner Res.
2002;
17
1081-1094
- 13
Bing-You R G, Denis M C, Rosen C J.
Low bone mineral density in adults with previous hypothalamic-pituitary tumors:
correlations with serum growth hormone response to GH-releasing hormone, insulin-like
growth factor I, and IGF binding protein 3.
Calcif Tissue Int.
1993;
52
183-187
- 14
Brill K T, Weltman A L, Gentili A, Patrie J T, Fryburg D A, Hanks J B. et al .
Single and combined effects of growth hormone and testosterone administration
on measures of body composition, physical performance, mood, sexual function,
bone turnover, and muscle gene expression in healthy older men.
J Clin Endocrinol Metab.
2002;
87
5649-5657
- 15
Brixen K, Kassem M, Eriksen E F, Nielsen H K, Flyvbjerg A, Mosekilde L.
Growth hormone (GH) and adult bone remodelling: the potential use of GH in treatment
of osteoporosis.
J Pediatr Endocrinol.
1993;
6
65-71
- 16
De Boer H, Blok G J, van Lingen A, Teule G J, Lips P, van der Veen E A.
Consequences of childhood-onset growth hormone deficiency for adult bone mass.
J Bone Miner Res.
1994;
9
1319-1326
- 17
Degerblad M, Elgindy N, Hall K, Sjöberg H -E, Thoren M.
Potent effect of recombinant growth hormone on bone mineral density and body
composition in adults with panhypopituitarism.
Acta Endocrinol.
1992;
126
387-393
- 18
Degerblad M, Bengtsson B A, Bramnert M, Johnell O, Manhem P, Rosen T, Thoren M.
Reduced bone mineral density in adults with growth hormone (GH) deficiency:
increased bone turnover during 12 months of GH substitution therapy.
Eur J Endocrinol.
1995;
133
180-188
- 19
Dennison E M, Hindmarsh P C, Kellingray S, Fall C H, Cooper C.
Growth hormone predicts bone density in elderly women.
Bone.
2003;
32
434-440
- 20
Dequeker J, Burssens A, Boullion R.
Dynamics of growth hormone secretion in patients with osteoporosis and in patients
with osteoarthrosis.
Horm Res.
1982;
16
353-356
- 21
Elgindy N, Grunditz R, Thoren M, Degerblad M, Sjöberg H E, Ringertz H.
Longterm follow-up of metacarpal cortical thickness and bone mineral density
in panhypopituitarism.
Radiol Diag.
1991;
32
326-330
- 22
Erdtsieck R J, Pols H A, Valk N K, van Ouwerkerk B M, Lamberts S W, Mulder P, Birkenhager J C.
Treatment of post-menopausal osteoporosis with a combination of growth hormone
and pamidronate: a placebo controled trial.
Clin Endocrinol.
1995;
43
557-565
- 23
Eriksen E F, Kassem M, Brixen K.
Growth hormone and insulin-like growth factors as anabolic therapies for osteoporosis.
Horm Res.
1993;
40
95-98
- 24
Ernst M, Froesch E R.
Growth hormone dependent stimulation of osteoblast-like cells in serum-free
cultures via local synthesis of insulin-like growth factor I.
Biochem Biophys Res Commun.
1988;
151
142-147
- 25
Finkenstedt G, Gasser R W, Hofle G, Watfah C, Fridrich L.
Effects of growth hormone (GH) replacement on bone metabolism and mineral density
in adult onset of GH deficiency: results of a double-blind placebo-controlled
study with open follow-up.
Eur J Endocrinol.
1997;
136
282-289
- 26
Franco P, Marelli O, Lattuada D, Locatelli V, Cocchi D, Muller E E.
Influence of growth hormone on the immunosuppressive effect of prednisolone
in mice.
Acta Endocrinol Copenh.
1990;
123
339-344
- 27
Gillberg P, Johansson A G, Blum W F, Groth T, Ljunghall S.
Growth hormone secretion and sensitivity in men with idiopathic osteoporosis.
Calcif Tissue Int.
2001;
68
67-73
- 28
Gillberg P, Mallmin H, Petren-Mallmin M, Ljunghall S, Nilsson A G.
Two years of treatment with recombinant human growth hormone increases bone
mineral density in men with idiopathic osteoporosis.
J Clin Endocrinol Metab.
2002;
87
4900-4906
- 29
Giovannucci E, Pollak M, Platz E A, Willett W C, Stampfer M J, Majeed N. et al .
Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and the risk of
colorectal adenoma and cancer in the Nurses’ Health Study.
Growth Horm IGF Res.
2000;
10
S30-S31
(Suppl A)
- 30
Giustina A, Bussi A R, Jacobello C, Wehrenberg W B.
Effects of recombinant growth hormone (GH) on bone and intermediary metabolism
in patients receiving chronic glucorticoid treatment with suppressed endogenous
GH response to GH-releasing hormone.
J Clin Endocrinol Metab.
1995;
80
122-129
- 31
Gomez J M, Gomez N, Fiter J, Soler J.
Effects of long-term treatment with GH in the bone mineral density of adults
with hypopituitarism and GH deficiency and after discontinuation of GH replacement.
Horm Metab Res.
2000;
32
66-70
- 32
Gonnelli S, Cepollaro C, Montomoli M, Gennari L, Montagnani A, Palmierei R, Gennari C.
Treatment of postmenopausal osteoporosis with recombinant human growth hormone
and salmon calcitonin: a placebo controlled study.
Clin Endocrinol.
1997;
46
55-61
- 33
Hansen T B, Brixen K, Vahl N, Jorgensen J O, Christiansen J S, Mosekilde L, Hagen C.
Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones,
calcium homeostasis, and bone metabolism in adults with acquired GH deficiency:
a double blind, randomized, placebo-controlled study.
J Clin Endocrinol Metab.
1996;
81
3352-3359
- 34
Holmes S J, Economou G, Whitehouse R W, Adams J E, Shalet S M.
Reduced bone mineral density in patients with adult-onset growth hormone deficiency.
J Clin Endocrinol Metab.
1994;
78
669-674
- 35
Holmes S J, Whitehouse R W, Swindell R, Economou G, Adams J E, Shalet S M.
Effect of growth hormone replacement on bone mass in adults with adult onset
growth hormone deficiency.
Clin Endocrinol.
1995;
42
627-633
- 36
Johannsson G, Rosen T, Bosacus I, Sjöström L, Bengtsson B -A.
Two years growth hormone (GH) treatment increases bone mineral content and density
in hypopituitary patients with adult-onset GH deficiency.
J Clin Endocrinol Metab.
1996;
81
2865-2873
- 37
Johansson A G, Lindh E, Blum W F, Kollerup G, Sorensen O H, Ljunghall S J.
Effects of growth hormone and insulin-like growth factor I in men with idiopathic
osteoporosis.
Clin Endocrinol Metab.
1996;
81
44-48
- 38
Johansson A G, Eriksen E F, Lindh E, Langdahl B, Blum W F, Lindahl A. et al .
Reduced serum levels of the growth hormone-dependent insulin-like growth factor
binding protein and a negative bone balance at the level of individual remodeling
units in idiopathic osteoporosis in men.
J Clin Endocrinol Metab.
1997;
82
2795-2798
- 39
Kann P, Piepkorn B, Schehler B, Piepenburg R, Lotz J, Bockisch A. et al .
Replacement therapy with recombinant human growth hormone (GH) in GH-deficient
adults: effects on bone metabolism and bone mineral density in a 2-year prospective
study.
Endocrinol Metab.
1995;
2
103-110
- 40
Kann P, Piepkorn B, Schehler B, Andreas J, Lotz J, Prellwitz W, Beyer J.
Effect of long-term treatment with GH on bone metabolism, bone mineral density
and bone elasticity in GH-deficient adults.
Clin Endocrinol.
1998;
48
561-568
- 41
Kann P H.
Growth Hormone in Anti-Aging Medicine: A Critical Review.
Aging Male.
2003;
6
257-263
- 42
Kassem M, Brixen K, Blum W, Mosekilde I, Eriksen E F.
No evidence for reduced spontaneous or growth hormone stimulated serum levels
of insulin-like growth factor (IGF)-1, IGP-II or IGF binding protein 3 in women
with spinal osteoporosis.
Eur J Endocrinol.
1994;
131
150-155
- 43
Kassem M, Brixen K, Mosekilde I, Eriksen E F.
Human marrow stromal osteoblast-like cells do not show reduced responsiveness
to in vitro stimulation with growth hormone in patients with postmenopausal
osteoporosis.
Calcif Tissue Int.
1994;
54
1-6
- 44
Kassem M, Brixen K, Blum W, Mosekilde I, Eriksen E F.
Normal osteoclastic and osteoblastic response to exogenous growth hormone in
patients with postmenopausal spinal osteoporosis.
J Bone Miner Res.
1994;
9
1365-1370
- 45
Kaufman J M, Taelman P, Vermeulen A, Vandeweghe M.
Bone mineral status in growth hormone deficient males with isolated and multiple
pituitary deficiencies of childhood onset.
J Clin Endocrinol Metab.
1992;
74
118-123
- 46
Kruse H P, Kuhlencordt F.
On an attempt to treat primary and secondary osteoporosis with human growth
hormone.
Horm Metab Res.
1975;
7
488-491
- 47
Kurland B S, Chan P K, Rosen C J, Bilezikian J P.
Normal growth hormone secretory reserve in men with idiopathic osteoporosis
and reduced circulating levels of insulin-like growth factor-I.
J Clin Endocrinol Metab.
1998;
83
2576-2579
- 48
Li G, Zeng M.
Relation of serum growth hormone and estradiol levels and osteoporosis in postmenopausal
women.
Chung Hua Tsa Chin Taipei.
1990;
70
16-19
- 49
Maor G, Hochberg Z, Von der Murk K, Heinegard D, Silberman M M.
Human growth hormone enhances chondrogenesis and osteogenesis in a tissue culture
system of chondro-progenitor cells.
Endocrinol.
1992;
125
1239-1245
- 50
Mucci L A, Tamimi R, Lagiou P, Trichopoulou A, Benetou V, Spanos E, Trichopoulos D.
Are dietary influences on the risk of prostate cancer mediated through the insulin-like
growth factor system?.
BJU Int.
2001;
87
814-20
- 51
Nishiyama K, Sugimoto T, Kaji H, Kanatani M, Kobayashi T, Chihara K.
Stimulatory effect of growth hormone on bone resorption and osteoclast differentiation.
Endocrinol.
1996;
137
35-41
- 52
Oertl H, Strasburger C J, Kann P, Quabbe H J.
Empfehlungen zur Indikation und Durchführung einer Wachstumshormon-Substitution
im Erwachsenenalter.
Dtsch Med Wochenschr.
1998;
123
883-886
- 53
Ohlsson C, Bengtsson B A, Isaksson O G, Andreassen T T, Slootweg M C.
Growth Hormone and bone.
Endocr Rev.
1998;
10
55-79
- 54
Ortoft G, Oxlund H.
Qualitative alterations of cortical bone in female rats after long-term administration
of growth hormone and glucocorticoid.
Bone.
1996;
18
581-590
- 55
Ott S M, Aitken M L.
Osteoporosis in patients with cystic fibrosis.
Clin Chest Med.
1998;
19
555-567
- 56
Papanicolaou D A, Wilder R L, Manolagos S C, Chrousos G P.
The pathophysiologic roles of interleukin-6 in human disease.
Ann Intern Med.
1998;
128
127-137
- 57
Rico H, Del-Rio A, Vila T, Patino R, Carrera F, Espinos D.
The role of growth hormone in the pathogenesis of postmenopausal osteoporosis.
Arch Intern Med.
1979;
139
1263-1265
- 58
Rosé n T, Hansson T, Granhed H, Szucs J, Bengtsson B -A.
Reduced bone mineral content in adult patients with growth hormone deficiency.
Acta Endocrinol.
1993;
129
201-206
- 59
Rosén T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G, Lindstedt G, Wilske J, Bengtsson B A.
Increased fracture rate in adults with growth hormone deficiency.
Endocrinol Metab.
1996;
3
121
- 60
Rubin C D.
Southwestern internal medicine conference: growth hormone - aging and osteoporosis.
Am J Med Sci.
1993;
305
120-129
- 61
Rudman D, Feller A G, Nagraj H S, Gergans G A, Lalitha P Y, Goldberg A F, Mattson D E.
et al .
Effects of human growth hormone in men over 60 years old.
N Engl J Med.
1990;
323
1-6
- 62
Saaf M, Hilding A, Thoren M, Troell S, Hall K.
Growth hormone treatment of osteoporotic postmenopausal women - a one year placebo-controlled
study.
Eur J Endocrinol.
1999;
140
390-399
- 63
Sartorio A, Conti A, Monzani M.
New markers of bone and collagen turnover in children and adults with growth
hormone deficiency.
Postgraduate Med J.
1993;
69
846-850
- 64
Shalet S M, Shavrikova E, Cromer M, Child C J, Keller E, Zapletalova J. et al .
Effect of Growth Hormone (GH) Treatment on Bone in Postpubertal GH-deficient
Patients: A 2-Year Randomized, Controlled, Dose-Ranging Study.
J Clin Endocrinol Metab.
2003;
88
4124-4129
- 65
Shaneyfelt T, Husein R, Bubley G, Mantzoros C S.
Hormonal predictors of prostate cancer: a meta-analysis.
J Clin Oncol.
2000;
18
847-853
- 66
Slootweg M C, van Buul-Offers S C, Herrmann-Erlec M PM, van der Meer J M, Duursma S A.
Growth hormone is mitogenic for fetal mouse osteoblasts but not for undifferentiated
bone cells.
J Endocrinol.
1988;
116
R11-R13
- 67
Sneppen S B, Hoeck H C, Kollerup G, Sorensen O H, Laurberg P, Feldt-Rasmussen U.
Bone mineral content and bone metabolism during physiological GH treatment in
GH-deficient adults - an 18-month randomised, placebo-controlled, double blinded
trial.
Eur J Endocrinol.
2002;
146
187-195
- 68
Stracke H, Schulz A, Moeller D, Rossol S, Schatz H.
Effect of growth hormone on osteoblasts and demonstration of somatomedin-C IGF-1
in bone organ culture.
Acta Endocrinol.
1984;
107
16-24
- 69
Strasburger C J, Schopohl J, Kann P, Oertel H.
Diagnostische Kriterien für die Indikation zur Wachstumshormonsubstitution bei
Erwachsenen.
Dtsch Med Wochenschr.
1997;
112
861-863
- 70
Sugimoto T, Nakaoka D, Nasu M, Kanzawa M, Sugishita T, Chihara K.
Effect of recombinant human growth hormone in elderly osteoporotic women.
Clin Endocrinol.
1999;
51
715-724
- 71
Sugimoto T, Kaji H, Nakaoka D, Yamauchi M, Yano S, Sugishita T. et al .
Effect of low-dose of recombinant human growth hormone on bone metabolism in
elderly women with osteoporosis.
Eur J Endocrinol.
2002;
147
339-348
- 72
Swolin-Eide D, Nilsson A, Ohlsson C.
Cortisol increases growth hormone-receptor expression in human osteoblast-like
cells.
J Endocrinol.
1998;
156
99-105
- 73
Tanaka H, Seino Y.
Does growth hormone treatment prevent corticosteroid-induced osteoporosis?.
Bone.
1996;
18
493-494
- 74
Vandeweghe M, Taelman P, Kaufman J M.
Short and long-term effects of growth hormone treatment on bone turnover and
bone mineral content in adult growth hormone-deficient males.
Clin Endocrinol.
1993;
39
409-415
- 75
Wüster C, Slenczka E, Ziegler R.
Increased prevalence of osteoporosis and arteriosclerosis in conventionally
substituted anterior pituitary insufficiency: need for additional growth hormone
substitution?.
Klin Wochenschr.
1991;
69
769-773
- 76
Wüster C, Abs R, Bengtsson B A, Bennmarker H, Feldt-Rasmussen U, Hernberg-Stahl E.
et al .
The influence of growth hormone deficiency, growth hormone replacement therapy,
and other aspects of hypopituitarism on fracture rate and bone mineral density.
J Bone Miner Res.
2001;
16
398-405
Prof. Dr. med. Peter Herbert Kann
Leiter des Bereichs Endokrinologie & Diabetologie, Klinikum der Philipps-Universität
Marburg
35033 Marburg
Phone: 06421/2863135
Fax: 06421/2862733
Email: kannp@med.uni-marburg.de